Extensive research effort ended up with the discovery of some clinical FXR ligands, including obeticholic acid, the only approved FXR modulator to date for PBC therapy, and under clinical phase III for the treatment of NASH [72]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.